Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Emanuele F. Kauffmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7634-4844; OpenAlex author ID A5056475542. Sources: OpenAlex.

Their work

Papers
23 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
88
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 5 papers · 2024: 5 papers · 2025: 4 papers · 2026: 3 papers

Papers 23

  1. Pancreatic ductal adenocarcinoma and pancreatic surgery in the 21st century: triumphs, turning points, and unresolved challenges. Co-author DOI 10.1007/s13304-025-02502-9↗
  2. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  3. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  4. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  5. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  6. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  7. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  8. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  9. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. First author DOI 10.1007/s13304-024-01860-0↗
  10. Minimally invasive versus open radical antegrade modular pancreatosplenectomy for pancreatic ductal adenocarcinoma: an entropy balancing analysis. First author DOI 10.1016/j.hpb.2023.09.013↗
  11. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  12. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. First author DOI 10.1097/sla.0000000000006248↗
  13. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  14. Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas. First author DOI 10.1007/s13304-023-01587-4↗
  15. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  16. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  17. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  18. Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. First author DOI 10.1007/s13304-020-00883-7↗
  19. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  20. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  21. Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. Co-author DOI 10.3389/fonc.2020.00064↗
  22. A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status. Co-author DOI 10.1007/s00464-018-6301-2↗
  23. Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Coh… Co-author DOI 10.3390/cancers11070939↗

Closest collaborators

The 25 strongest of 88 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ugo Boggi · 10 shared papers, 2019–2026 · strength 1.58
  2. Niccolò Napoli · 7 shared papers, 2019–2026 · strength 0.98
  3. Riccardo Casadei · 4 shared papers, 2023–2026 · strength 0.72
  4. Alessandro Zerbi · 4 shared papers, 2023–2026 · strength 0.72
  5. Allegra Ripolli · 3 shared papers, 2025–2026 · strength 0.70
  6. Sergio Alfieri · 3 shared papers, 2024–2026 · strength 0.60
  7. Enrico Vasile · 4 shared papers, 2019–2026 · strength 0.59
  8. Daniela Campani · 5 shared papers, 2019–2023 · strength 0.57
  9. Marc G. Besselink · 3 shared papers, 2023–2026 · strength 0.52
  10. Giuseppe Fusai · 3 shared papers, 2023–2026 · strength 0.52
  11. Kongyuan Wei · 2 shared papers, 2025–2026 · strength 0.41
  12. V. Egorov · 2 shared papers, 2025–2026 · strength 0.41
  13. Gregory G. Tsiotos · 2 shared papers, 2025–2026 · strength 0.41
  14. Yuichi Nagakawa · 2 shared papers, 2025–2026 · strength 0.41
  15. Benedetto Ielpo · 2 shared papers, 2025–2026 · strength 0.41
  16. Elena B. Rangelova · 2 shared papers, 2025–2026 · strength 0.41
  17. Emilio Vicente · 2 shared papers, 2025–2026 · strength 0.41
  18. Roberto Coppola · 2 shared papers, 2025–2026 · strength 0.41
  19. Andrea Cacciato Insilla · 4 shared papers, 2019–2021 · strength 0.38
  20. Caterina Vivaldi · 3 shared papers, 2019–2021 · strength 0.30
  21. Thilo Hackert · 2 shared papers, 2023 · strength 0.22
  22. Edoardo Rosso · 1 shared paper, 2024 · strength 0.20
  23. Claudio Fiorillo · 1 shared paper, 2024 · strength 0.20
  24. Fabrizio Panaro · 1 shared paper, 2024 · strength 0.20
  25. Cecilia Ferrari · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.